AzTrials
AzTrials

Periodontal DiseasesNCT03510702

SCREENING OF EPIGENETIC BIOMARKERS (miRNAs) IN THE GINGIVAL SULCUS

An observational study of Periodontal Diseases and Inflammatory Response, run by University of Valencia at 1 site in Spain.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Epigenetics has produced a high impact in biomedical research and is providing new biomarkers for the diagnosis and prognosis of diseases. In addition, epigenetics is also contributing to analyze the molecular causes underlying diseases, even so periodontal diseases as it has been recently reviewed. Read more about this study

Who is it for?
Ages 30 to 60 yearsHealthy volunteers can take part
Conditions the study is for
Periodontal Diseases, Inflammatory Response
What is being tested?
Levels of epigenetic biomarkers present in the gingival fluid and its possible relationship with bone metabolism.
How many people
40 participants
Where
1 siteSpain
Study dates
15 Sep 2017to Jul 2019
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 to 60 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Study population: Patients attending to the university who meet the inclusion criteria.

Who may be able to join

  • Group of periodontal patients:
  • Clinical criteria: at least 3 locations in unirradicular teeth with PD 6 mm. 3 samples will be taken from each of these 3 locations (9 total samples). Third molars are not included in the study.
  • Patients not treated periodontally.
  • 30-60 years.
  • Periodontally healthy group:
  • 1. Absence of clinical and radiographical periodontal pathology.

Who cannot join

  • Group of periodontal patients:
  • Aggressive Periodontal Disease (Armitage, 1999).
  • Patients with controlled periodontal disease with plaque and gingival indexes ≤20%.
  • Patients with systemic diseases or taking medications that alter bone metabolism (Osteoporosis, arthritis, hormonal treatment, bisphosphonates, anti-inflammatory, immunosuppressants, etc ...).
  • Patients with antibiotic, anti-inflammatory or contraceptive treatment in the previous 3 months or taking antiaggregants in the last 7 days before taking the sample.
  • Smokers (> 10 cig. /day).
Show all 12Show fewer
  • Pregnant or breast-feeding.
  • Periodontally healthy group:
  • Patients with systemic diseases or taking medications that alter bone metabolism (Osteoporosis, arthritis, hormonal treatment, bisphosphonates, anti-inflammatory, immunosuppressant...).
  • Patients with antibiotic, anti-inflammatory or contraceptive treatment in the previous 3 months or taking antiaggregants in the last 7 days before taking the sample.
  • Smokers (> 10 cig/day).
  • Pregnant or breast-feeding.

Trial locations and contacts

1 site in 1 country.

Spain1 site, 1 recruiting
  • Ana Fuenmayor Garcés

    Valencia

    Ana Fuenmayor Garcés, Postgraduate student, 0034680964117, anafuenmayorgarces@gmail.com

    Recruiting

Other trials in Spain

About this study

Official title: Screening of Epigenetic Biomarkers (miRNA) in the Gingival Sulcus

Epigenetics has produced a high impact in biomedical research and is providing new biomarkers for the diagnosis and prognosis of diseases. In addition, epigenetics is also contributing to analyze the molecular causes underlying diseases, even so periodontal diseases as it has been recently reviewed. In this regard, changes in the methylation of genes codifying for pro-inflammatory and anti-inflammatory cytokines has been previously reported. miRNAs are very promising biomolecules to be used as biomarkers because miRNAs act as signaling molecules and participate in many biological processes, such as cellular development, differentiation, and apoptosis. The high stability of circulating miRNAs in the RNase-rich environment of the bloodstream and also in different biospecimens used in clinical routine, make these biomolecules an optimal source of candidate biomarkers. In fact, miRNAs have demonstrated their value as dynamic biomarkers in a wide variety of human diseases. Therefore, miRNAs can be used for the monitoring of periodontal disease.

The objective of this research is to analyze the levels of bone remodeling RANKL / OPG biomolecular markers, and the epigenetic regulation of these proteins to identify promising biomarkers of periodontal disease.

Read more

Material and Methods. Levels of RANKL and OPG will be measured in the gingival crevicular fluid (GCF) to assess the state of bone. These samples will be sent to the lab for quantification by ELISA method.

Furthermore, new epigenetic biomarkers based on the identification of high stable microRNAs will be identified by qRT-PCR in GCF as feasible tools for diagnosis and monitoring of wide range of disease, including periodontal disease.

Being tested
Levels of epigenetic biomarkers present in the gingival fluid and its possible relationship with bone metabolism.
Keywords
Epigenetic., microRNA., Periodontitis.
Medical subject headings
Periodontal Diseases, Periodontitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Levels of epigenetic biomarkers present in the gingival fluid and its possible relationship with bone metabolism.Diagnostic test

    Once the anamnesis has been done, all the records corresponding to the Gingival Index and Plaque Index, in both groups are taken.

    Subsequently, samples of gingival crevicular fluid are taken for the screening of epigenetic biomarkers.

Study groups in NCT03510702
Study groupRoleWhat they receive
Periodontal patients.Taking gingival Crevicular fluid.
Receives: Diagnostic Test: Levels of epigenetic biomarkers present in the gingival fluid and its possible relationship with bone metabolism.
Periodontally healthy patients.Taking gingival Crevicular fluid.
Receives: Diagnostic Test: Levels of epigenetic biomarkers present in the gingival fluid and its possible relationship with bone metabolism.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. microRNA in gingival crevicular fluid (physiological parameter).

    Insert the Perio Paper® tip in gingival sulcus until resistance is felt and leave it for 30 seconds.

    Measured: 2 years.

Secondary outcomes (6)
  1. Probing depth.

    Probing depth will be measured in six sites (disto-buccal, mid-buccal, mesio-buccal, disto-palatal, mid-palatal and mesio- palatal) of every teeth with a Williams Probe PQ-OW 208 396. This probe is used by gently hanging pressure into a pocket measuring 20 grams in weight.

    Measured: 2 years.

  2. Bleeding on probing.

    Full mouth bleeding score (FMBS) will be calculated based on scores of 0 (no bleeding) or 1 (bleeding) after probing for PD. The usual thing to do is to measure at 4 points for each tooth but we have modified the index and we valorate them at 6 points. (disto-buccal, mid-buccal, mesio-buccal, disto-palatal, mid-palatal and mesio- palatal).

    Measured: 2 years.

  3. Clinical recession.

    Clinical recession will be measured in the same six sites as before between the Amelocemental junction and the gingival margin.

    Measured: 2 years.

  4. Plaque score of Silness y löe: (1964)

    The Plaque will be scored as follows:

    Score 0 = No plaque

    Score 1 = A film of plaque adhering to the free gingival margin and adjacent area of the tooth. The plaque may be seen in situ only after application of disclosing solution or by using the probe on the tooth surface.

    Score 2 = Moderate accumulation of soft deposits within the gingival pocket, or on the tooth and gingival margin, which can be seen with the naked eye.

    Score 3 = Abundance of soft matter within the gingival pocket and/or on the tooth and gingival margin.

    The usual thing to do is to evaluate at 4 points for each tooth but we have modified the index and we will evaluate at 6 points. (disto-buccal, mid-buccal, mesio-buccal, disto-palatal, mid-palatal and mesio- palatal)

    Measured: 2 years.

  5. Dental movility of Mïller 1950

    Class I

    Up to 1 mm of movement in a horizontal direction.

    Class II Greater than 1 mm of movement in a horizontal direction. Class III

    Excessive horizontal movement and vertical movement.

    Measured: 2 years.

  6. Furcation affection.

    Class I:

    The level of bone loss allows for the insertion of the periodontal Nabers probe into the concavity of the root trunk. Furcation defect is less than 3 mm is depth.

    Class II The level of bone loss allows for the insertion of a periodontal probe into the furcation area between the roots. Furcation defect is at least 3 mm in depth (and thus, in general, surpassing half of the buccolingual thickness of the tooth) but not through-and-through (i.e. there is still some interradicular bone attached to the angle of the furcation.

    15

    Class III The level of bone loss allows for "through and through" access of the furcation area. Buccal to lingual on lower molars. Buccal to mesio-palatal and disto-palatal on upper molars. Furcation defect encompassing the entire width of the tooth so that no bone is attached to the angle of the furcation.

    Measured: 2 years.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Apr 2018
  2. Study start15 Sep 2017
  3. Primary completionJul 2019 (estimated)
  4. Study completionJul 2019 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03510702
Sponsor's protocol ID
H1510580113419
Status last verified
Apr 2018
First submitted
1 Apr 2018
Last updated
27 Apr 2018
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Periodontal Diseases and Inflammatory Response, run by University of Valencia at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 27 Apr 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

microRNA in gingival crevicular fluid (physiological parameter). (time frame: 2 years.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Apr 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in